Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
2011
Аутори:
Chappell, William HSteelman, Linda S
Long, Jacquelyn M
Kempf, Ruth C
Abrams, Stephen L
Franklin, Richard A
Baesecke, Joerg
Stivala, Franca
Donia, Marco
Fagone, Paolo
Malaponte, Graziella
Mazzarino, Maria C
Nicoletti, Ferdinando
Libra, Massimo
Maksimović-Ivanić, Danijela
Mijatović, Sanja
Montalto, Giuseppe
Cervello, Melchiorre
Laidler, Piotr
Milella, Michele
Tafuri, Agostino
Bonati, Antonio
Evangelisti, Camilla
Cocco, Lucio
Martelli, Alberto M
McCubrey, James A
Тип документа:
Приказ (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Integral components of these pathways, Ras, B-Raf, PI3K, and PTEN are also activated/inactivated by mutations. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of these pathways can contribute to chemotherapeutic drug resistance, proliferation of cancer initiating cells (CICs) and premature aging. This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging. Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways play key roles in the regulation of normal and malignant cell growth. Inhibitors targeting these pathways have many potential uses from suppression of cancer, proliferative diseases as well as aging.
Извор:
Oncotarget, 2011, 2, 3, -164Финансирање / пројекти:
- Fondazione del Monte di Bologna e Ravenna (IGF-1 RBAP10447J)
DOI: 10.18632/oncotarget.240
ISSN: 1949-2553
PubMed: 21411864